Literature DB >> 9579539

Photodynamic therapy of B16F10 murine melanoma with lutetium texaphyrin.

K W Woodburn1, Q Fan, D Kessel, Y Luo, S W Young.   

Abstract

Photodynamic therapy (PDT) of pigmented melanoma has generally been unsuccessful because of insufficient light penetration in such tissues. In this study, the responsiveness of the heavily pigmented B16F10 murine melanoma to lutetium texaphyrin (PCI-0123), a water-soluble sensitizer with strong absorbance in the near infrared (700-760 nm), was examined. These studies were carried out in both normal and ApoE deficient C57BL/6 mice. The latter strain exhibits a lipoprotein profile more like humans (low density lipoprotein > high density lipoprotein) than rodents (high density lipoprotein >> low density lipoprotein). Under optimal conditions of drug dose, light dose, and interval between drug administration and irradiation--the median survival time of C57BL/6 tumor bearing mice was approximately doubled (29 d) compared with tumor bearing control animals (13 d). The life-span of the ApoE knockout mice was greater (33 d) than the C57BL/6 animals (23 d) when irradiation occurred 3 h after administration of a 10 micromol per kg drug dose. The greater efficacy of PDT in the ApoE deficient mice was associated with more rapid clearance of drug from the blood, greater accumulation of sensitizer in tumor tissue, and substantially greater drug binding to the very low density lipoprotein/low density lipoprotein plasma fraction. Confocal laser scanning microscopy showed that the predominant subcellular site of photosensitizer binding was to melanosomes; costaining was performed with Mel-5. Melanosomes are susceptible to oxidative stress. Photo-oxidation, mediated by PCI-0123 PDT, could potentially overload an already highly oxidized stressed state leading to cell death. The good tissue penetration depth achieved by PCI-0213 mediated PDT and the activation of melanosomes makes PDT of pigmented melanoma, for the first time, clinically relevant.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9579539     DOI: 10.1046/j.1523-1747.1998.00182.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  20 in total

1.  High Aspect Ratio Nanotubes Formed by Tobacco Mosaic Virus for Delivery of Photodynamic Agents Targeting Melanoma.

Authors:  Karin L Lee; Bradley L Carpenter; Amy M Wen; Reza A Ghiladi; Nicole F Steinmetz
Journal:  ACS Biomater Sci Eng       Date:  2016-03-23

2.  Interstitial fluorescence spectroscopy in the human prostate during motexafin lutetium-mediated photodynamic therapy.

Authors:  Jarod C Finlay; Timothy C Zhu; Andreea Dimofte; Diana Stripp; S Bruce Malkowicz; Theresa M Busch; Stephen M Hahn
Journal:  Photochem Photobiol       Date:  2006 Sep-Oct       Impact factor: 3.421

3.  Stable synthetic bacteriochlorins overcome the resistance of melanoma to photodynamic therapy.

Authors:  Pawel Mroz; Ying-Ying Huang; Angelika Szokalska; Timur Zhiyentayev; Sahar Janjua; Artemissia-Phoebe Nifli; Margaret E Sherwood; Christian Ruzié; K Eszter Borbas; Dazhong Fan; Michael Krayer; Thiagarajan Balasubramanian; Eunkyung Yang; Hooi Ling Kee; Christine Kirmaier; James R Diers; David F Bocian; Dewey Holten; Jonathan S Lindsey; Michael R Hamblin
Journal:  FASEB J       Date:  2010-04-12       Impact factor: 5.191

4.  Noninvasive radiofrequency field destruction of pancreatic adenocarcinoma xenografts treated with targeted gold nanoparticles.

Authors:  Evan S Glazer; Cihui Zhu; Katheryn L Massey; C Shea Thompson; Warna D Kaluarachchi; Amir N Hamir; Steven A Curley
Journal:  Clin Cancer Res       Date:  2010-12-01       Impact factor: 12.531

Review 5.  Recent advances in the prevention and treatment of skin cancer using photodynamic therapy.

Authors:  Baozhong Zhao; Yu-Ying He
Journal:  Expert Rev Anticancer Ther       Date:  2010-11       Impact factor: 4.512

6.  Optical properties of human prostate at 732 nm measured in mediated photodynamic therapy.

Authors:  Timothy C Zhu; Andreea Dimofte; Jarod C Finlay; Diana Stripp; Theresa Busch; Jeremy Miles; Richard Whittington; S Bruce Malkowicz; Zelig Tochner; Eli Glatstein; Stephen M Hahn
Journal:  Photochem Photobiol       Date:  2005 Jan-Feb       Impact factor: 3.421

Review 7.  Melanoma resistance to photodynamic therapy: new insights.

Authors:  Ying-Ying Huang; Daniela Vecchio; Pinar Avci; Rui Yin; Maria Garcia-Diaz; Michael R Hamblin
Journal:  Biol Chem       Date:  2013-02       Impact factor: 3.915

Review 8.  A critical review of the clinical effects of therapeutic irradiation damage to the brain: the roots of controversy.

Authors:  Carol L Armstrong; Kunsang Gyato; Abdel W Awadalla; Robert Lustig; Zelig A Tochner
Journal:  Neuropsychol Rev       Date:  2004-03       Impact factor: 7.444

9.  Unique diagnostic and therapeutic roles of porphyrins and phthalocyanines in photodynamic therapy, imaging and theranostics.

Authors:  Leanne B Josefsen; Ross W Boyle
Journal:  Theranostics       Date:  2012-10-04       Impact factor: 11.556

10.  In vitro photodynamic therapy with chlorin e6 leads to apoptosis of human vascular smooth muscle cells.

Authors:  Magdalena Wawrzyńska; Wojciech Kałas; Dariusz Biały; Ewa Zioło; Jacek Arkowski; Walentyna Mazurek; Leon Strzadała
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2010-02       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.